NEW YORK, March 17, 2017 /PRNewswire/ -- The parties to hundreds of Taxotere lawsuits pending in the U.S. District Court, Eastern District of Louisiana have been directed to meet and confer regarding a date for Science Day. Per an Order issued on March 7, 2017, the Court has offered two possible dates, including Wednesday, April 19, 2017 or Wednesday, May 3, 2017. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740)
"Science Day is a standard event in many large, complex proceedings, and will provide both sides in the Taxotere permanent alopecia litigation an opportunity to apprise the Court of the scientific and medical issues central to these claims. This is usually done in an off-the-record, non-adversarial manner," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free case reviews to breast cancer patients and others whose hair failed to grow back following chemotherapy with Taxotere.
Taxotere and Permanent Alopecia
Taxotere is a chemotherapy agent marketed by Sanofi-Aventis that is indicated to treat breast cancer and a number of other malignancies. Court records indicate that nearly 800 Taxotere lawsuits have been filed in the District of Eastern Louisiana on behalf of plaintiffs who allegedly experienced permanent hair loss following treatment with the drug. While alopecia is a common side effect of chemotherapy, plaintiffs charge that hair loss associated with Taxotere is more likely to be permanent compared to alternative, equally effective medications.
Taxotere was initially approved by the U.S. Food & Drug Administration (FDA) in 1996. However, it wasn't until December 2015 that mention of permanent alopecia was added to the drug's U.S. labeling. According to plaintiffs, Sanofi has long provided information regarding the potential for permanent hair loss to individual patients and regulatory agencies overseas, while the label in this country only included a generic, vague, and insufficient warning that "hair generally grows back".
Cancer patients who allegedly experienced permanent hair loss following chemotherapy with Taxotere may be entitled to compensation for their emotional distress and other damages. To learn more about filing a Taxotere lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/taxotere-lawsuit-attorneys-at-bernstein-liebhard-llp-note-preparation-for-science-day-in-federal-hair-loss-litigation-300425468.html
SOURCE Bernstein Liebhard LLP